Strong Global Footprint
Our Geographical Reach
United States Of America
The world’s largest market for pharmaceuticals, USA has always been on Torrent Pharma’s strategic radar. Torrent Pharma Inc., our subsidiary, serves the growing need of our products in the market.
We have 101 ANDAs approval with 34 approvals in pipeline. We aim to strengthen our position in the market by launching complex generics which include specialty oral solids (Oncology) and value added medicines 505(b)(2) in the coming times.
Europe
One of the most regulated and evolved Pharma markets worldwide, the EU has been a veritable learning ground for Torrent. Proven expertise in product development and a strong regulatory knowledge have helped in developing a highly robust product portfolio comprising of different TAs including CNS, CVS and GI among others. Our wholly owned subsidiaries in Germany, UK and Malta spearhead Torrent Pharma’s operations in the EU territory. Germany and UK markets have shown impressive growth over the last 5 years
Germany
Torrent forayed into Germany in 2005 with acquisition of Heumann Pharma Generics, a Pfizer Group Company. Heumann’s broad product portfolio coupled with our low-cost manufacturing facilities provide a good strategic market position to us in one of the biggest pharmaceutical markets in the globe.
Today, Torrent enjoys 4th position in the market and is ranked No. 1 amongst the Indian players in the market.
UK
Torrent Pharma (UK) Ltd is one of the fastest growing generic pharmaceutical companies within the UK; the most mature generics market in Western Europe. Through robust supplies from Torrent Pharmaceuticals and several portfolio acquisition deals, we have built a robust pipeline of products and a current range of over 100 molecules.
Brazil
Torrent entered the Brazilian market 24 years ago. Currently, ranked 1st in covered market, it is ranked 15th in prescriptions exhibiting the 5th highest growth in branded products amongst the top 50 Pharmaceuticals companies in the Country. Torrent is also the biggest Indian Company in terms of sales in Brazil contributing to almost 65% of sales by Indian companies in Brazil. Our strong relationship with Neurologists, Psychiatrists and Cardiologists have helped us accomplish the same. We have 56 products approved at Anvisa with 24 of products in CNS segment, 19 in the Cardio Vascular and 5 in Oral Anti Diabetic/Obesity (OAD) segments and 8 cosmeceuticals products. In view of the high growth in the pure generic segment, we are building our product portfolio in the CV, CNS, OAD and other therapies. The company has more than 50 products of branded generics and generics in the pipeline in Brazil.
Emerging markets is a mix of regulated and semi regulated markets comprising of Russia, CIS, South East Asia, Asia Pacific, Africa, Middle East, Central and Latin America. Torrent Pharma’s products in the Therapeutic areas of Diabetology, Cardiovascular and Central Nervous System are promoted and supported by our sales and support team of over 450 people.
African Countries
Zimbabwe
Torrent has the distinction of being one of the foremost Indian Company to get its products registered in this market and is also amongst the leading Indian company in the Zimbabwean market. With a rich portfolio of 54 products and a strong pipeline of 7 products under registration, we are well poised to extract the high potential offered by this market.
Kenya
Kenya being the gateway to East African Markets is a territory of strategic significance for Torrent. Having started our marketing operations in 1994, the past couple of years have witnessed consolidation of the marketing efforts. With 42 product registered and 16 more in the offing, our focus is on brand building.
Uganda
Strategic selection of products encompassing a wide range of therapeutic indications has found profound acceptance by the members of medical fraternity in this country. The aim is to intensify Torrent's focus on Cardio Vascular and CNS products, which has been our forte over the years. Present product portfolio entails an assortment of 26 products with 1 more in pipeline.
Nigeria
Extending its territorial fortification to Western Africa, Torrent made successful forays into Nigeria, which by far is one of the biggest markets in West Africa. Having already secured registrations for a handful of its specialized products. Present product portfolio entails an assortment of 23 products.
South Africa
Having received SAHPRA approval for the manufacturing facility of Oral Solids and about 27 product registrations & 3 products in pipeline, Torrent’s pathway is open to explore Africa’s sizeable and the most regulated market.
Asian Countries
Sri Lanka
Torrent's consistent sales growth over the past decade displays the confidence of medical fraternity in our brands. With over 32 products in the market and another 30 in the pipeline, we remain committed towards providing a wide range of products to the Sri Lankan market. Torrent is well known in the island for its neuro-psychiatry, cardio vascular and gastro intestinal range.
Vietnam
Vietnam is one of the major market in the South East Asian arena for Torrent. Currently, 62 products are registered & 53 are in pipeline including cosmeceuticals. We started our operations in Vietnam in the year 1996, with representative office in Ho Chi Minh City, the commercial capital of Vietnam. Torrent in Vietnam now has a mixed basket of products, with a focus on brand building to ensure long-term business & growth. In continuation of our Indian tradition, Torrent has earned a distinct image for itself in Vietnam in the field of cardiology & neuropsychiatry.
Myanmar
Torrent Pharma initiated the marketing operations in Myanmar in 1995. We have more than 58 products registered in the country with another 9 in the pipeline including cosmeceuticals. Four distributors across the country distribute our registered products. With strong product portfolio in cardiovascular and decent presence in neuropsychiatry, Torrent is poised to create a specialty-focused platform in the country. Our focus is on strengthening the product basket, creating brand equity and launching new molecules in the market.
Philippines
Torrent’s first subsidiary in Asia has been in Philippines considering the marketing opportunities available in this densely populated island nation. Today, Torrent is amongst the top 20 companies in the country and is the No. 1 branded Generic Company in CNS segment.We have 102 products registered in the country with another 15 products in the pipeline including cosmeceuticals.
Malaysia
Laboratories Torrent (Malaysia) Sdn Bhd , a subsidiary of Torrent Pharma in Malaysia , kicked off its operations in March 2012 to further strengthen presence in the South East Asian Market. The major focus areas are CNS and CV therapies. Today, Torrent is one of the fastest growing companies in the country.We have 52 products registered in the country with another 15 products in the pipeline including cosmeceuticals.
Australia
Torrent Pharma has created a distinct presence in the Pacific region with its subsidiary - Torrent Australasia Pvt Ltd (TAPL). We have received 15 product approvals in the regulated markets of the region.
Latin America & Caribbean Markets
Torrent aims to penetrate the Latin American market with its high quality products and extensive product portfolio. Strong economic performance in this region is expected to fuel our growth in the coming years. In addition, recent regulatory developments will create further market opportunities in these countries, particularly for generic producers in both the private and public sectors. With over 180 registrations in important markets like Bolivia, El Salvador, Venezuela, Colombia, Peru, Chile, Panama, Guatemala, Ecuador, Dominican Republic, Costa Rica, Honduras, Jamaica and Trinidad & Tobago
Mexico
Torrent entered Mexico Market in 2010, primarily with CNS products. Today we are the 6th ranked company in the covered market. We are active amongst highest growing companies in the CNS segment. We have 23 registered products out of which 13 products are being marketed. We have been growing through intensive CRM with the key specialists like Neurologists, Psychiatrists and Geriatricians.
In addition to continuing the consolidation in the CNS segment; we aim to strengthen our business by launching new products in other therapeutic areas as well.
Russia & CIS
Torrent Pharma’s foray into the international markets began with operations in the erstwhile Soviet Union in 1983. In Russian Federation, Torrent has a wholly owned subsidiary and its own warehouse for closer reach to the customers. Torrent, through its own field force of over 65 sales professionals has strong presence across major cities in Russia. With product registrations in Russia and CIS , Torrent has sizeable presence in therapeutic areas of Cardio Vascular, Neurology , Psychiatry and Gastroenterology.
In addition to continuing the consolidation in the CNS segment; we aim to strengthen our business by launching new products in other therapeutic areas as well.
